| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 2, Alpha 2,3-ST 2, Beta-galactoside alpha-2,3-sialyltransferase 2, Gal-NAc6S, Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase, ST3Gal II, ST3GalII, ST3GalA2, Sialyltransferase 4B, SIAT4-B, ST3GAL2, SIAT4B |
| Entrez GeneID | 6483 |
| WB Predicted band size | 40.2kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This ST3GAL2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 55-89 amino acids from the N-terminal region of human ST3GAL2. |
+ +
以下是关于ST3GAL2(N-term)抗体的模拟参考文献示例(实际文献需根据具体数据库检索确认)：
---
1. **"Characterization of a novel anti-ST3GAL2 antibody targeting the N-terminal domain for glycan analysis in cancer cells"**
*Author: Tanaka, K. et al.*
摘要：本研究开发了一种针对ST3GAL2蛋白N端结构域的多克隆抗体，并通过免疫印迹和免疫组化验证其特异性。该抗体成功用于检测多种癌细胞系中ST3GAL2的表达水平，并揭示其与肿瘤转移的相关性。
2. **"ST3GAL2-mediated sialylation regulates neuronal cell adhesion and axonal guidance"**
*Author: Müller, S. et al.*
摘要：利用N端特异性ST3GAL2抗体，研究发现该酶在小鼠脑发育过程中高表达，并通过调控神经细胞表面聚糖结构影响轴突导向和突触形成，提示其在神经发育中的关键作用。
3. **"A functional role of ST3GAL2 in breast cancer progression: Insights from antibody-based inhibition assays"**
*Author: Chen, L. et al.*
摘要：通过靶向ST3GAL2 N端的抗体阻断其酶活性，实验证明ST3GAL2通过修饰整合素β1的糖基化促进乳腺癌细胞迁移和侵袭，为治疗靶点提供依据。
4. **"Differential expression of ST3GAL2 isoforms in Alzheimer's disease revealed by N-terminal specific antibodies"**
*Author: Rossi, G. et al.*
摘要：使用两种N端抗体对比分析发现，ST3GAL2在阿尔茨海默病患者脑组织中存在异构体表达差异，可能与β-淀粉样蛋白沉积导致的神经炎症相关。
---
**注**：以上为模拟示例，实际文献需通过PubMed、Google Scholar等平台以关键词“ST3GAL2 antibody N-terminal”或“ST3GAL2 (N-term)”检索确认。
The ST3GAL2 (N-term) antibody is designed to target the N-terminal region of the ST3 beta-galactoside alpha-2.3-sialyltransferase 2 (ST3GAL2) protein, a key enzyme in glycosylation. ST3GAL2 belongs to the sialyltransferase family and catalyzes the transfer of sialic acid to terminal galactose residues on glycoproteins and glycolipids, forming α-2.3 linkages. This post-translational modification influences cell-cell interactions, immune responses, and signal transduction. The N-terminal domain of ST3GAL2 is critical for its catalytic activity and substrate binding.
Research using this antibody often focuses on studying ST3GAL2's role in cancer, inflammation, and neurological disorders. Overexpression of ST3GAL2 has been linked to tumor progression, metastasis, and altered immune evasion in cancers like glioblastoma and melanoma. The antibody is widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to detect protein expression, localization, and regulation.
Validated for specificity, the antibody typically recognizes a ~40-45 kDa band corresponding to ST3GAL2. Its applications extend to exploring sialylation-related pathways in disease models or biomarker discovery. Dysregulation of ST3GAL2 is also implicated in autoimmune conditions and neurodegenerative diseases, making this antibody a valuable tool for mechanistic and therapeutic studies.
×
